VENABLE LLP for ENDO PHARMACEUTICALS INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues relating to incentives for life sciences research. H.R. 160- Protect Medical Innovation Act of 2015. Tax treatment of inverted companies. Tax issues in mergers and acquisitions of US firms.
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILLIAM R NORDWIND | — |
| ROBERT L SMITH | — |
Copyright/Patent/Trademark CPT
Oversight of implementation of the America Invents Act. Issues relating to patent settlements. H.R. 9 -- The Innovation Act. S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015. Issues relating to misuse of the inter pares review process.
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILLIAM R NORDWIND | — |
| ROBERT L SMITH | — |
Health Issues HCR
Issues relating to prescription drug abuse; Issues relating to incentives for tamper-resistant formulations; H.R. 471 Ensuring Patient Access and Effective Drug Enforcement Act of 2015; Issues relating to the labeling of generic drugs; Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H.R. 106. Issues relating to bioequivalence and related administrative procedures; Issues relating to incentives for tamper-resistant formulation, Issues relating to Medicare Part D rebates; Issues relating to products containing high doses of acetaminophen. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to Opioids. H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015. S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILLIAM R NORDWIND | — |
| ROBERT L SMITH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.